EFFECT OF THE COMBINED ANTIHYPERTENSIVE THERAPY WITH TARGET BLOOD PRESSURE ACHIEVEMENT ON INTRARENAL BLOOD FLOW IN PATIENTS WITH TYPE 2 DIABETES

Aim. To compare the dynamics of intrarenal vascular resistance (IRVR), circadian blood pressure (BP) profile and glomerular filtration rate (GFR) in patients with arterial hypertension (HT) and type 2 diabetes mellitus (DM) who achieved the target BP levels (<130/80 mmHg) due to long-term combined antihypertensive therapy with or without renin-angiotensin-aldosterone system (RAAS) inhibitors. Material and methods. Patients (n=61) with HT and DM without clinical symptoms of nephroangiopathy were included into the open randomized study , 59 of these patients completed study. Patients of Group 1 (n=41) received therapy with valsartan (n=20), 80–160 mg/day , or perindopril (n=21), 5–10 mg/day , in combination with indapamide retard, 1.5 mg/day , and amlodipine, 5–10 mg/day. Patients of Group 2 (n=18) received amlodipine (5–10 mg/day) in combination with indapamide retard (1.5 mg/day) and metoprolol succinate (50–100 mg/day). Initially and after 30–32 weeks of therapy the following examinations were performed: duplex ultrasound scanning of the main renal (MRA) and intrarenal arteries (IRA) with resistive index (RI) calculation, ambulatory BP monitoring (ABPM), GFR calculation (by Cockcroft-Gault formula). Results. The target BP levels were achieved in all patients of both groups. Patient’s baseline characteristics including age, sex, duration of disease, office BP , GFR, RI in MRA and IRA did not differ in the groups as well as decrease in office BP due to treatment. However patients of Group 2 had higher levels of systolic BP and systolic BP load at night time than these in patients of Group 1 during all period of the treatment. In patients of Group 2 RI in MRA and arcuate IRA were increased from 0.67±0.06 to 0.69±0.06 (p=0.02) and from 0.62±0.07 to 0.64±0.06 (p=0.02), respectively. The increase in IRA was positively associated with systolic BP at night time in these patients (r=0.6; p=0.01). There were no significant changes of IRA in Group 1 totally. At the same time, initially high IRVR decreased in 61% of patients. GFR increased in patients of Group 2 (p=0.01), while dynamics of GFR was not found in patients of Group 1. Conclusion. Achievement of target BP levels due to antihypertensive therapy not including RAAS inhibitors resulted in increase in IRVR that associated with the lack of systolic BP reduction at night time.

1. Chair H., Sowers J.R. National high blood pressure education program working group report on hypertension in diabetes. Hypertension 1994; 23: 145–158.

2. Dedov I.I., Shestakova M.V., editors. Algorithms for specialized medical care to patients with diabetes mellitus. Moscow: Meditsinskoe informatsionnoe agentstvo; 2006. Russian (Дедов И.И., Шестакова М.В., редакторы. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Москва: Медицинское информационное агентство; 2006).

3. National guidelines for diagnosis and treatment of hypertension (fourth revision). Sistemnye Gipertenzii 2010; (3): 5–26. Russian (Национальные рекомендации по диагностике и лечению артериальной гипертонии (четвертый пересмотр). Системные Гипертензии 2010; (3): 5–26).

4. The Task Force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension. J Hypertens 2007; 25:1105–1187.

5. Okura T., Watanabe S., Miyoshi K., et al. Intrarenal and carotid hemodynamics in patients with essential hypertension. Am J Hypertens 2004;17:240–244.

6. Radermacher J.J. Echo–Doppler to predict the outcome for renal artery stenosis. Nephrologie 2002;15 Suppl 6: 69–76.

7. Ueda H., Ishimura E., Shoji T. et al. Factors affecting progression of renal failure in patients with type 2 diabetes. Diabetes Care 2003; 26: 1530–1534.

8. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2002; 25 suppl 1: s5–s20.

9. Reid M.H., Maskay R.S., Lantz B.M. Noninvasive blood flow measurements by Doppler ultrasound with application to renal artery flow determination. Invest Radiol 1980; 15 (4): 323–331.

10. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16(1): 31–41.

11. Ноllenberg N.K., Price D.A., Fisher N.D., et al. Glomerular hemodynamics and the renin-an-giotensin-system in patients with type 1 diabetes mellitus. Kidn Inter 2003; 63:172–178.

12. Koshel'skaya O.A., Zhuravleva O.A., Karpov R.S. Features of intrarenal Doppler indices of blood flow in diabetes mellitus type 2 and its association with hypertension. Arterial'naya Gipertenziya 2009;15(6): 652–659. Russian (Кошельская О.А., Журавлёва О.А., Карпов Р.С. Особенности допплерографических показателей внутрипочечного кровотока при сахарном диабете типа 2 и его ассоциации с артериальной гипертонией. Артериальная Гипертензия 2009;15(6): 652–659).

13. Sasaguri M., Matsumoto N., Noda K., et al. Amlodipine lowers blood pressure without increasing the renin-angiotensin system in patients with essential hypertension. Eur J Clin Pharmacol 1997; 53: 197– 201.

14. Sanjuliani A.F., de Abreu V.G., Francischetti E.A. Selective imidazoline agonist moxonidine in obese hypertensive patients. Int J Clin Pract 2006; 60(5): 621–629.

15. Schrader J., Lunders S., Kulschewski A. et al. for MOSES study group. Morbidity and mortality after stroke. Eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005; 36:1218–1226.

16. Segura J., Praga M., Campo C. et al. Combination is better than monotherapy with ACE inhibitor or angiotensin receptor antagonist at recommended doses. J Renin Angiotensin Aldosterone Syst 2003; 4 (1): 43–47.

17. Julius S., Kjeldsen S.E., Weber M., et al. Outcomes in hypertensive patients at high cardiovascular risk treated with valsartan- or amlodipine-based regimens: VALUE, a randomized trial. Lancet 2004; 363: 2022–2031.

18. Tatti P., Paahron M., Byington R.P., et al. Outcome results of fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21: 597–603.

19. Kulikov A.N., Bobrov L.L. The action of certain antihypertensive agents on circadian blood pressure profile in patients with essential hypertension. TERRA Medica Nova 2003; (4): 5–10. Russian (Ку-ликов А.Н., Бобров Л.Л. Действие некоторых антигипертензивных средств на суточный профиль артериального давления у больных с гипертонической болезнью. TERRA Medica Nova 2003; (4): 5–10).

20. Sidorenko B.A., Preobrazhenskiy D.V., Batyraliev T.A. ACE inhibitors and AT1 – blockers in clinical practice. Part Three. Moscow: ZAO Prezid-Al'yans; 2004. Russian (Сидоренко Б.А., Преображенский Д.В., Батыралиев Т.А. Ингибиторы АПФ и АТ1 — блокаторы в клинической практике. Часть третья. Москва: ЗАО Презид-Альянс; 2004).

21. Neutel J., Weber M., Pool J. et al. Valsartan, a new angiotensin II antagonist: antihypertensive effects over 24 hours. Clin Ther 1997; 19: 447–457.

22. Belousov Yu.B., Gratsianskaya A.N. Clinical pharmacology of amlodipine (Norvasc). Moscow: Universum Pablishing; 1998. Russian (Белоусов Ю.Б., Грацианская А.Н. Клиническая фармакология амлодипина (Норваска). Москва: Универсум Паблишинг; 1998).

23. Ol'binskaia LI, Vartanova OA, Khapaev BA. The antihypertensive and antianginal activity of Dilren, long-acting calcium antagonist. Ter Arkh 1994;66(12):13–6. Russian (Ольбинская Л.И., Вартанова О.А., Хапаев Б.А. Антигипертензивная и антиангинальная активность дилрена — антагониста кальция пролонгированного действия. Терапевтический Архив 1994; (12): 13–16).

24. Yakimenko E.A., Severgina I.A., Polivoda S.N. The experience of prolonged use of a fixed combination of lisinopril and amlodipine in the treatment of hypertensive patients in conjunction with coronary artery disease. Arterial'naya Gipertenziya 2009; 5(7): 34–40. Russian (Якименко Е.А., Севергина И.А., Поливода С.Н. Опыт длительного применения фиксированной комбинации лизиноприла и амлодипина в лечении больных гипертонической болезнью в сочетании с ишемической болезнью сердца. Артериальная Гипертензия 2009; 5(7): 34–40).

25. Lizogub I. V. Long-term use of amlodipine in patients with essential hypertension. Ukrainskiy kardiologicheskiy zhurnal 2002; 5: 45–50. Russian (Лизогуб И. В. Длительное применение амлодипина в лечении пациентов с гипертонической болезнью. Украинский Кардиологический Журнал 2002; 5: 45–50).

26. Ovdienko T.N. Features of the influence of beta-blockers on the circadian blood pressure profile and its response to exercise testing in patients with essential hypertension. Kardiologiya Ukrainy 2008; 12: 21–27. Russian (Овдиенко Т.Н. Особенности влияния бета-адреноблокаторов на суточный профиль артериального давления и его реакцию на нагрузочные тесты у больных с гипертонической болезнью. Кардиология Украины 2008; 12: 21–27).

27. Dzizinskiy A.A., Protasov K.V., Fedorishina O.V. Dynamics of pulse pressure during treatment with am-lodipine and carvedilol in hypertensive patients. Lechashchiy Vrach 2008; 6: 43–48. Russian (Дзизинский А.А., Протасов К.В., Федоришина О.В. Динамика пульсового давления на фоне лечения амлодипином и карведилолом у больных артериальной гипертонией. Лечащий Врач 2008; 6: 43–48).

28. Bangalore S., Sawhney S., Messerli F.H. Relation of beta-blocker-induced heart rate lowering and car-dioprotection in hypertension. J Am Coll Cardiol 2008; 52: 1982–1989.

29. Avezedo E.R., Kubo T., Mak S., et al. Nonselective versus selective b-adrenergic receptor blockade on congestive heart failure: differential effects on sympathetic activity. Circulation 2001; 104: 1213–1225.

30. Platt J., Rubin J., Ellis J. Diabetic nephropathy: evaluation with renal duplex Doppler US. Radiology 1994; 190: 343–346.

31. Kuntsevich G.I., Barabashkina A.V., Anosov O.L. Features of duplex scanning with color Doppler mapping in the diagnosis of microangiopathy in diabetic patients. Vizualizatsiya v Klinike 1995; 7: 17–

32. Russian (Кунцевич Г.И., Барабашкина А.В., Аносов О.Л. Возможности дуплексного сканирования с цветным допплеровским картированием в диагностике микроангиопатии у больных сахарным диабетом. Визуализация в Клинике 1995; 7: 17–21).

33. Pontremoli R., Viazzi F., Martinoli C., et al. Increased renal resistive index in patients with essential hypertension: a marker of target organ damage. Nephrology, dialysis, transplantaton 1999; 14(2): 360– 365.

34. Okura T., Jotoku M., Irita J., et al. Association between cystatin C and inflammation in patients with essential hypertension. Clinical and experimental nephrology 2010; 14: 584–588.

35. Leoncini G., Martinoli C., Viazzi F., et al. Changes in renal resistive index and urinary albumin excretion in hypertensive patients under long-term treatment with lisinopril or nifedipine GITS. Nephron 2002; 90: 169–173.

36. Karpov R.S., Vrublevskiy A.V., Efimova E.V., Koshel'skaya O.A. Doppler evaluation of renal blood flow dynamics under the influence of cilazapril in combination with arterial hypertension and type II diabetes at an early stage of nephropathy. Kardiologiia 1999; 4: 16–20. Russian (Карпов Р.С., Врублевский А.В., Ефимова Е.В., Кошельская О.А. Допплерографическая оценка динамики почечного кровотока под влиянием цилазаприла при сочетании артериальной гипертонии и сахарного диабета II типа на ранней стадии нефропатии. Кардиология 1999; 4: 16–20).

37. Logacheva I.V., Ivanova I.V., Tsyplyashova I.V., et al. Dynamics of the morphofunctional indices of heart and kidney disease in hypertensive patients in connection with the use of noliprel. Arterial'naya Gipertenziya 2004; 10(4): 57–62. Russian (Логачева И.В., Иванова И.В., Цыпляшова И.В., и соавт. Динамика морфофункциональных показателей сердца и почек у больных артериальной гипертонией в связи с использованием нолипрела. Артериальная Гипертензия 2004; 10(4): 57–62).

38. Caruso D., D’Avino M., Acampora C., et al. Effects of losartan and chlorthalidone on blood pressure and renal vascular resistance index in non-diabetic patients with essential hypertension and normal renal function. J Cardiovasc Pharmacol 2004; 44: 520–524.

39. Bakris G, Hester A, Weber M et al. The diabetes subgroup baseline characteristics of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial. J Cardiometab Syndr 2008;3(4):229–33.

40. Weidmann P., et al. Therapeutic efficacy of different antihypertensive drugs in human diabetic nephropathy: an updated meta-analysis. Nephrol Dial Transplant 1995; 10 (Suppl 9): 39–45.

41. Lea J., Green T., Hebert L. et al. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med 2005; 165 (8): 947–953.